Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m ...

Wedbush is removing Geron (GERN) from the firm’s Best Ideas List due to its investment price discipline. Wedbush has an Outperform rating on ...

Shares of Geron (NASDAQ:GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Geron reported a ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

H.C. Wainwright downgraded Geron (GERN) to Neutral from Buy without a price target following the Q4 report. The shift in guidance for interim ...

B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...

Geron (GERN) delivered earnings and revenue surprises of -100% and 4.67%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

You may begin. Good morning, everyone. Welcome to the Geron Corporation fourth quarter and full year 2024 earnings conference call. I am Aron Feingold, Geron's Vice President of Investor Relations ...

FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Geron Corp. (GERN) on Wednesday reported a loss of $25.4 million in its fourth quarter. The Foster City, California-based company said it had a ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...